New York, Feb 7, 2026, 11:00 EST — The market has shut down for the day.
- Johnson & Johnson ended Friday’s session at $239.99, up 0.9%.
- Beasley Allen got tossed from New Jersey state talc litigation by an appeals court; a related motion at the federal level hasn’t been decided yet.
- J&J on this day shared initial 12-month pilot results for its investigational AFib device platform during a cardiology meeting
Johnson & Johnson (JNJ) stock climbed 0.9% to finish Friday at $239.99, landing close to its intraday peak, after a New Jersey appeals court ejected a major plaintiffs’ firm from part of the company’s talc lawsuits. Roughly 8.3 million shares traded hands.
The talc docket’s timing is crucial—still the company’s top headline risk, and a wild card that’s tough for investors to quantify. A single courtroom twist can jolt the stock, regardless of how stable the drug-and-device segment looks.
J&J wants the spotlight on its latest products, particularly in MedTech, a segment where device launches and clinical updates can shift sentiment fast. On this day, investors digested both new earnings and a court decision.
Beasley Allen has been tossed from New Jersey’s consolidated talc litigation, after a state appellate panel concluded the firm crossed an ethical line by working with a former J&J lawyer privy to privileged material. “The extraordinary and malicious nature of the ethical violation warrants the most fulsome remediation, including disqualification from all related litigation,” said J&J litigation head Erik Haas. The ruling affects roughly 3,600 cases still active in New Jersey, while J&J’s similar bid for disqualification in federal court—where more than 67,500 cases are underway—has yet to be decided. Reuters
J&J flagged 12-month results from its OMNY-AF pilot, which is testing the experimental OMNYPULSE system in patients with paroxysmal AFib—a type of irregular heartbeat. Out of 30 people in the study, 90% hit the main efficacy target a year in, according to the company. No procedure-related adverse events were reported. Also notable: zero fluoroscopy was used in 56.7% of procedures, skipping the X-ray technique commonly needed to guide catheters. While OMNYPULSE isn’t approved anywhere yet, J&J’s VARIPULSE pulsed-field ablation system has signoff in the U.S. and other regions. The company also pointed to a 0.22% neurovascular event rate in a group of 6,811 patients after it updated its workflow.
Pulsed-field ablation, a more recent approach to treating AFib, works by using electrical pulses—not heat—to target tissue responsible for abnormal rhythms. For investors, this puts the technology right where growth in cardiac devices meets the uncertainties of execution: safety concerns, extra regulatory eyes, and the unpredictable speed with which hospitals take up new tech.
J&J shares moved higher Friday, though the stock trailed several big-name pharma rivals during a strong session for U.S. equities—the S&P 500 rallied almost 2%. Pfizer put up a 2.8% gain, Abbott added 1.6%, outpacing J&J, per market data.
Still, tail risks linger. The New Jersey decision leaves the broader talc litigation unresolved, and an appeal or the outstanding federal motion could change things yet again. As for the AFib data, it’s preliminary—small pilot group, early days. The investigational platform hasn’t cleared the regulatory hurdle either.
Looking at Monday, traders are on alert for any reaction to the legal headline, plus fresh takeaways from the AF Symposium talks. The company’s next big event lands March 3, with management set for a fireside chat at 11:10 a.m. Eastern during the TD Cowen health care conference.
